ClearPoint Neuro Reports Record Q1 2025 Revenue

Clearpoint Neuro, Inc. ( (CLPT) ) has released its Q1 earnings. Here is a breakdown of the information Clearpoint Neuro, Inc. presented to its investors.

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company that specializes in precise navigation for brain and spine procedures, offering both clinical products and preclinical development services. In its first quarter of 2025, ClearPoint Neuro reported record revenue of $8.5 million, marking an 11% increase from the previous year, driven by a significant 70% growth in single-use navigation and therapy products. The company also achieved FDA clearance for its ClearPoint 3.0 Software, which is expected to contribute to further revenue and case volume growth.

The company’s financial performance was highlighted by a 104% increase in consumable product revenue, including biologics and drug delivery cannulas, and a 70% rise in neurosurgery navigation and therapy revenue. However, capital equipment and software revenue saw a 63% decline due to timing in the installation of new equipment. Despite these mixed results, ClearPoint Neuro maintained a gross margin of 60%, slightly up from the previous year.

ClearPoint Neuro’s operating expenses rose by 29% to $11.3 million, primarily due to increased personnel-related costs and higher product development expenses. The company ended the quarter with $12.4 million in cash and cash equivalents, down from $20.1 million at the end of 2024, largely due to operating expenses and tax payments related to equity awards.

Looking ahead, ClearPoint Neuro reaffirms its full-year 2025 revenue outlook of $36.0 million to $41.0 million. The company remains optimistic about its strategic objectives, supported by a new long-term credit facility and equity investment, which provide financial flexibility to pursue growth opportunities in the biopharma and laser therapy markets.